| Previous close | 89.67 |
| Open | 90.42 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 88.42 - 90.61 |
| 52-week range | 76.45 - 106.66 |
| Volume | |
| Avg. volume | 1,757,202 |
| Market cap | 111.109B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 17.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.33 (3.71%) |
| Ex-dividend date | 06 May 2022 |
| 1y target est | N/A |
- GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagitis in the European Union (EU) Dupixent now approved to treat five diseases with underlying type 2 inflammation in the EU TARRYTOWN,
- GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placeboDupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagi
- GlobeNewswire
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only targeted medicine in the EU for these young childrenRecommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of lifeIn Europe, about 80,000 children aged 6 months to 5 years
